|
| Press Releases |
|
 |
|
| Wednesday, August 14, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of Alzheimer's disease (AD). more info >> |
|
| Tuesday, August 6, 2024 |
|
|
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation |
| Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows. more info >> |
|
| Wednesday, July 31, 2024 |
|
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
| Monday, July 29, 2024 |
|
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
| Thursday, July 25, 2024 |
|
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
| Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Tuesday, July 16, 2024 |
|
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社（本社：東京都、以下 佐藤製薬）と締結したことをお知らせします。 more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「レケンビ」（レカネマブ）がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ®」（一般名：レカネマブ）について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
AsiaMedic continues growth streak with 23% increase in revenue for First Half ended 30 June 2024
Aug 14, 2024 21:00: JST
|
|
|
Femto Technologies Reports Increase in Revenue and Transition to Net Profit for the Second Quarter of 2024
Aug 14, 2024 21:00 HKT/SGT
|
|
|
Dr.Friend Puppy, Exhibits at Global Pet Show, Targeting Overseas Markets
Aug 14, 2024 21:00: JST
|
|
|
Dr.Friend Puppy, Exhibits at Global Pet Show, Targeting Overseas Markets
Aug 14, 2024 20:00 HKT/SGT
|
|
|
AsiaMedic continues growth streak with 23% increase in revenue for First Half ended 30 June 2024
Aug 14, 2024 20:00 HKT/SGT
|
|
|
新能源助推綠色轉型 中國港能打造智慧能源新藍圖
Aug 14, 2024 18:42 HKT/SGT
|
|
|
新能源助推绿色转型 中国港能打造智慧能源新蓝图
Aug 14, 2024 18:19 HKT/SGT
|
|
|
Nissin Foods Becomes a Constituent of MSCI Global Micro Cap Index (MSCI Hong Kong Index)
Aug 14, 2024 18:14: JST
|
|
|
Kincora and AngloGold Ashanti's First Drilling Program
Aug 14, 2024 18:09 HKT/SGT
|
|
|
Experience Eternal Romance with Exquisite Blue Diamonds by ALUXE
Aug 14, 2024 18:00 HKT/SGT
|
|
|
Nissin Foods Becomes a Constituent of MSCI Global Micro Cap Index (MSCI Hong Kong Index)
Aug 14, 2024 17:14 HKT/SGT
|
|
|
日清食品為MSCI全球微型股指數（MSCI香港指數）成份股之一
Aug 14, 2024 17:05 HKT/SGT
|
|
|
NIA's 'SITE 2024' Achieves Record Success at the MHESI 'SCI POWER FOR FUTURE THAILAND' Fair
Aug 14, 2024 17:00 HKT/SGT
|
|
|
日清食品为MSCI全球微型股指数（MSCI香港指数）成份股之一
Aug 14, 2024 16:42 HKT/SGT
|
|
|
Genes Tech Group Announces 2024 Interim Results
Aug 14, 2024 16:16 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
